Ontology highlight
ABSTRACT:
SUBMITTER: Giunta EF
PROVIDER: S-EPMC7307282 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Giunta Emilio Francesco EF De Falco Vincenzo V Napolitano Stefania S Argenziano Giuseppe G Brancaccio Gabriella G Moscarella Elvira E Ciardiello Davide D Ciardiello Fortunato F Troiani Teresa T
Therapeutic advances in medical oncology 20200619
<i>BRAF-V600</i> mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments in these patients regardless of their mechanisms of action and toxicities. However, an upfront therapeutic strategy is still controversial. In fact, waiting for results of ongoing clinical trials and for new biomarkers, clinicians should base their decision on the clinical characteristics of the patient and on the ...[more]